Objective: The aim of this study is to compare the hemodynamic response to intubation with and without oral Ivabradine in patients undergoing laparoscopic surgery.

Methods: This was a prospective, randomized, double-blind study conducted on 60 patients scheduled for laparoscopic surgery under general anesthesia. The patients were randomly divided into two groups: Group A received 5 mg oral Ivabradine one hour prior to surgery, while Group B received a placebo. Hemodynamic parameters, including heart rate (HR) and mean arterial pressure (MAP) were recorded at baseline, after intubation, and at 1, 3, 5, and 10 minutes after intubation.

Results: The HR and MAP increased significantly in both groups after intubation. However, the increases in HR and MAP were significantly lower in Group A than in Group B at all time points after intubation.

Conclusion: Oral Ivabradine given one hour prior to surgery effectively blunts the hemodynamic response to intubation in patients undergoing laparoscopic surgery under general anesthesia. It is a safe and cost-effective alternative to traditional methods of controlling the hemodynamic response to intubation.

1. Smith AJ, Goodman NW. The hypertensive response to intubation. Do researchers acknowledge previous work? Can J Anaesth 1997;44:9 13.
2. Foëx P, Higham H. Preoperative fast heart rate: A harbinger of perioperative adverse cardiac events. Br J Anaesth 2016;117:271 4
3. Fox EJ, Sklar GS, Hill CH, Villanueva R, King BD. Complications related to the pressor response to endotracheal intubation. Anesthesiology 1977;47:524-5.
4. Bruder N, Ortega D, Granthil C. Consequences and prevention methods of hemodynamic changes during laryngoscopy and intratracheal intubation. Ann Fr AnesthReanim 1992;11:57 71.
5. Yusuf S, Camm AJ. Sinus tachyarrhythmias and the specific bradycardic agents: A marriage made in heaven? J CardiovascPharmacolTher 2003;8:89 105.
6. De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 2008;10:550 5
7. FDA Approves Corlanor to Treat Heart Failure. Available from: https:// www.fda.gov/Drugs/InformationOnDrugs/ucm446899.htm. [Last accessed on 2015 May 15].
8. Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I (f) inhibitor, in stable angina: A randomized, double blind, multicentered, placebo controlled trial. Circulation 2003;107:817 23.
9. Kumar S, Vohra J. Ivabradine: Appropriate treatment for inappropriate sinus tachycardia. Heart Rhythm 2010;7:1324-5.
10. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost Brama A, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo controlled trial. Lancet 2010;376:886 94.
11. Lakatta EG, DiFrancesco D. What keeps us ticking: A funny current, a calcium clock, or both? J Mol Cell Cardiol 2009;47:157 70.
12. Riccioni G. Ivabradine: An intelligent drug for the treatment of ischemic heart disease. Molecules 2012;17:13592 604.
13. Baruscotti M, Bucchi A, Difrancesco D. Physiology and pharmacology of the cardiac pacemaker (“funny”) current. Pharmacol Ther 2005;107:59 79.
14. Fox K, Ford I, Steg PG, TardifJC, Tendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014;371:1091 9.
15. Raghuram CG, Singh DR, Kabra AV. Attenuation of haemodynamic response to laryngoscopy and endotracheal intubation using intra oral ivabradine: A clinical study. J Evol Med Dent Sci 2014;3:9944 55

Dr M. Ravikumar

Associate Professor Department of Anaesthesiology, Govt Chengalpattu Medical College